These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10713017)

  • 1. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
    Rich S; Rubin L; Walker AM; Schneeweiss S; Abenhaim L
    Chest; 2000 Mar; 117(3):870-4. PubMed ID: 10713017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminorex, dexfenfluramine, and primary pulmonary hypertension.
    Kramer MS; Lane DA
    J Clin Epidemiol; 1998 Apr; 51(4):361-4. PubMed ID: 9539893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
    McCann UD; Seiden LS; Rubin LJ; Ricaurte GA
    JAMA; 1997 Aug; 278(8):666-72. PubMed ID: 9272900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug-clinics. The hue and cry over central appetite suppressants!].
    Scheen AJ
    Rev Med Liege; 1997 Sep; 52(9):613-5. PubMed ID: 9441348
    [No Abstract]   [Full Text] [Related]  

  • 5. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
    Delcroix M; Kurz X; Walckiers D; Demedts M; Naeije R
    Eur Respir J; 1998 Aug; 12(2):271-6. PubMed ID: 9727773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anorexigen-related cardiopulmonary toxicity.
    Gross SB; Lepor NE
    Rev Cardiovasc Med; 2000; 1(2):80-9, 102. PubMed ID: 12457145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.
    Abenhaim L; Moride Y; Brenot F; Rich S; Benichou J; Kurz X; Higenbottam T; Oakley C; Wouters E; Aubier M; Simonneau G; Bégaud B
    N Engl J Med; 1996 Aug; 335(9):609-16. PubMed ID: 8692238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appetite suppressants and primary pulmonary hypertension in the United Kingdom.
    Thomas SH; Butt AY; Corris PA; Egan JJ; Higenbottam TW; Madden BP; Waller PC
    Br Heart J; 1995 Dec; 74(6):660-3. PubMed ID: 8541174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal trends and drug exposures in pulmonary hypertension: an American experience.
    Walker AM; Langleben D; Korelitz JJ; Rich S; Rubin LJ; Strom BL; Gonin R; Keast S; Badesch D; Barst RJ; Bourge RC; Channick R; Frost A; Gaine S; McGoon M; McLaughlin V; Murali S; Oudiz RJ; Robbins IM; Tapson V; Abenhaim L; Constantine G
    Am Heart J; 2006 Sep; 152(3):521-6. PubMed ID: 16923424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iatrogenic pulmonary artery hypertension].
    Weitzenblum E; Kessler R; Chaouat A
    Rev Mal Respir; 1996; 13(2):133-9. PubMed ID: 8711232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenfluramines, idiopathic pulmonary primary hypertension and cardiac valve disorders: facts and artifacts.
    Tellier P
    Ann Med Interne (Paris); 2001 Nov; 152(7):429-36. PubMed ID: 11965083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The longitudinal effects of fenfluramine-phentermine use.
    Fleming RM; Boyd LB
    Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension.
    Strother J; Fedullo P; Yi ES; Masliah E
    Arch Pathol Lab Med; 1999 Jun; 123(6):539-40. PubMed ID: 10383810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary pulmonary hypertension associated with the use of fenfluramine derivatives.
    Simonneau G; Fartoukh M; Sitbon O; Humbert M; Jagot JL; Hervé P
    Chest; 1998 Sep; 114(3 Suppl):195S-199S. PubMed ID: 9741568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
    Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
    N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
    Mark EJ; Patalas ED; Chang HT; Evans RJ; Kessler SC
    N Engl J Med; 1997 Aug; 337(9):602-6. PubMed ID: 9271482
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe heart valve disease on appetite suppressants.
    Prescrire Int; 1998 Feb; 7(33):19-20. PubMed ID: 10183395
    [No Abstract]   [Full Text] [Related]  

  • 18. Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
    Dillon KA; Putnam KG; Avorn JL
    JAMA; 1997 Oct 22-29; 278(16):1320. PubMed ID: 9343461
    [No Abstract]   [Full Text] [Related]  

  • 19. Further cases of valvular heart disease associated with fenfluramine-phentermine.
    Graham DJ; Green L
    N Engl J Med; 1997 Aug; 337(9):635. PubMed ID: 9280830
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of obesity with drugs.
    Hirsch J
    Am J Clin Nutr; 1998 Jan; 67(1):2-4. PubMed ID: 9440366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.